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Objectives. To evaluate the clinical efficacy and feasibility of an expiratory muscle training (EMT) device (Respilift) applied
to patients recovering from recent open cardiothoracic surgery (CTS). Design. Prospective, double-blind, 14-day randomised-
controlled trial. Participants and Setting. A total of 60 inpatients recovering from recent CTS and early admitted to a pulmonary
rehabilitation program. Interventions. Chest physiotherapy plus EMT with a resistive load of 30 cm H
2
O for active group and
chest physiotherapy plus EMT with a sham load for control group. Measures. Changes in maximal expiratory pressure (MEP)
were considered as primary outcome, while maximal inspiratory pressures (MIP), dynamic and static lung volumes, oxygenation,
perceived symptoms of dyspnoea, thoracic pain, and well being (evaluated by visual analogic scale—VAS) and general health status
were considered secondary outcomes. Results. All outcomes recorded showed significant improvements in both groups; however,
the change of MEP (+34.2mmHg, 𝑃 < 0.001 and +26.1%, 𝑃 < 0.001 for absolute and % of predicted, resp.) was significantly higher
in active group. Also VAS dyspnoea improved faster and more significantly (𝑃 < 0.05) at day 12, and 14 in active group when
compared with control. The drop-out rate was 6%, without differences between groups. Conclusions. In patients recovering from
recent CTS, specific EMT by Respilift is feasible and effective. This trial is registered with ClinicalTrials.gov NCT01510275.
1. Introduction
In the postoperative period patients undergoing cardio-
thoracic surgery (CTS) have an increasing risk to develop
pulmonary complications such as atelectasis, pneumonia, or
pleural effusion, potentially leading to increasing length of
stay and rate of hospital mortality [1, 2]; in these patients
symptoms (dyspnoea and pain) are usually perceived as
disabling, both linked to the reduction of lung ventilation
following the chest opening.
Pulmonary rehabilitation (PR) is a nonpharmacological
intervention aimed at improving exercise tolerance, symp-
toms, and general health status in patients with chronic
respiratory diseases [3, 4]. In subjects recovering recent tho-
racopulmonary surgery for lung resection, pleural decortica-
tion [5, 6], or coronary artery bypass graft (CABG) [7, 8], the
application of a rehabilitation course including specifically
pulmonary reexpansion and/or respiratory muscle training
represents a potentially useful intervention, especially if
applied in a period less than one week after the surgery (e.g.,
when patients were directly transferred from surgical unit)
[5, 9, 10].
In mild to very severe patients suffering from chronic
obstructive pulmonary disease (COPD), the application of
two recent easy-to-use respiratory devices (Respivol and
Respilift) has been shown to enhance the pulmonary vol-
umes, the respiratory muscle performance (maximal inspi-
ratory pressure (MIP) and maximal expiratory pressure
(MEP)), and the perceived dyspnoea when used alone [11] or
even in combination [12].
Aim of our study was to evaluate the clinical efficacy and
feasibility of specific expiratory muscle training (EMT) by
the Respilift device applied to patients recovering from recent
open CTS.
2 BioMed Research International
2. Methods
2.1. Study Design and Patients. This was a prospective,
double-blind, parallel-assignment, AND randomized-
controlled study carried out at an Italian rehabilitation centre
(Villa Pineta Hospital, Pavullo nel Frignano, Modena, Italy)
for a period of 14 consecutive days. The hospital board
approved the trial, which was conducted in accordance with
the declaration of Helsinki and good clinical practice rules
and recorded on ClinicalTrial.gov website with identification
code NCT01510275. Selected patients gave their written
informed consent to participate in the study. Figure 1 shows
the study flow diagram, according to CONSORT statement
for nonpharmacologic treatment [13].
In a period between October 2010 and May 2012 we
enrolled and consecutively selected 60 adult patients admit-
ted to an inpatient PR course one to three weeks after open
CTS. At the enrolment, patients with severe or unstable
clinical condition (e.g., respiratory distress) or comorbidities
requiring strict medical monitoring (e.g., congestive heart
failure) were excluded from the study. Patients showing
inability to use the respiratory device or to collaborate with
the attending physiotherapist were excluded also. Patients
with new occurring clinical signs and worsening condition
after enrolment were considered as dropouts.
2.2. Interventions. By a monoblock electronically generated
list at the enrolment patients were randomly allocated to the
active or control group. Patients allocated in active group
used Respilift, a device developing EMT with a resistive
load of 30 cm H
2
O integrated into and in conjunction
with Respivol, a volume-targeted incentive spirometer (see
Figure 2); patients in control group used the same devices but
with a sham load (no resistance) for Respilift. Each training
session consisted of 15 minutes and was performed twice
a day; a respiratory physiotherapist (deputed to the study),
unaware of the study aim and group allocation, assisted
all enrolled patients. With the intent to familiarizing with
Respilift and Respivol eligible patients were instructed to use
devices for a 2-hour training period.
In the morning of each day of the study, by a pressure
manometer, Respilift was previously tested in order to define
an accurate resistive load. Inspiratory volume as well as the
inspiratory flowwere set on two calibrated scales and visually
displayed by plates which are lifted up and kept suspended by
a sustained, slow, and deep inspiration. Expiratory resistive
load of 30 cm H
2
O has been applied by a disposable blinded
plastic column with one-way valve and containing a floating
mobile indicator which defined the target load for the
patients. A mouthpiece tube endowed with a filter connected
this resistor to one side of the volume chamber.
Chest physiotherapy program (similarly for active and
control groups) was performed by manually assisted lung
expansion (Exercise a` Debit Inspiratoire Controle` (EDIC)
and Expiration Lente Totale Glotte Ouverte en Infralate´ral
(ELTGOL)) as recommended [3, 6] for 20 consecutive
minutes twice a day; a short preliminary description of
the procedures was given by the attending physiotherapist,
previously instructed to homogenise the type and duration
of all the activities.
2.3. Measurements and Outcomes. At enrolment (day-0)
demographics and general characteristics were collected.
Outcome measures were recorded at day 8 and at the end of
study (day 14) while data on individuals’ perceived symptoms
(dyspnoea, thoracic pain, and well being) were recorded
every 2 days from the enrolment (day 0, day 2, day 4, day 6,
day 8, day 10, day 12, day 14).
2.3.1. Primary Outcome. Maximal expiratory pressures
(MEP) were performed by means of a specific module
(Masterscope; Jaeger; Hoechberg, Germany) recording
maximal pressures against an occlusive mouth resistance
at both total lung capacity and functional residual volume;
values were recorded as absolute values (mmHg) and as
percentage (%) of predicted according to the reference
equations [14], and the best of three measurements was
considered for the study.
2.3.2. Secondary Outcomes. The samemodule andmodalities
of MEP were used to measure maximal inspiratory pressure
(MIP) but maximal pressures against an occlusive mouth
resistance at functional residual volume; valueswere recorded
as absolute values (mmHg) and as percentage (%) of pre-
dicted.
Forced and static lung capacities and volumes (FEV
1
:
forced expiratory volume in the first second, FVC: forced vital
capacity, VC: vital capacity, IC: inspiratory capacity, TLC:
total lung capacity, and RV: residual volume) were taken by
pletismography (Pletismography Platinum DX, MedGraph-
ics, Saint Paul, MN, USA), expressed both in absolute values
(litres) and as percentage of predicted [15].
With the patient breathing in a room air, a radial arterial
gas analysis was performed by an automated analyzer (Model
850; Chiron Diagnostics; Medfield, MA, USA): measure-
ments of arterial carbon dioxide pressure (PaCO
2
), arterial
oxygen pressure (PaO
2
), and the ratio of partial arterial oxy-
gen pressure to the fraction of inspired oxygen (PaO
2
/FiO
2
)
were collected.
According to the AmericanThoracic Society (ATS) state-
ment [16] a 6min walking test (6 MWT) was performed to
evaluate exercise capacity; moreover, chronic dyspnoea (by
medical research council (MRC) score) [17] and individual’s
health-related status (by SF36: short form 36 health survey
questionnaire) [18]were detected as pre-to-post (on day 0 and
day 14) measures of the rehabilitation course.
A time trend (change) in visual analogic scale (VAS) [19]
was used to assess perceived sensation of dyspnoea, thoracic
pain, and well being.
2.4. Statistical Analysis. Analysis of study variables was
performed using a statistical software package (SPSS 17 for
Windows).
Based on our preliminary data in similar patient [5], a
minimum sample size of 27 patients per arm was required in
order to obtain a statistical power of 90%, to be able to detect
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Figure 1: Study flow diagram. Study measures collected by demographic data (a), pletismography (b), arterial gas analysis (c), respiratory
muscle performance (d), 6min walking test (e), chronic MRC dyspnoea scale (f), health status-SF 36 (g), and patient-related symptoms
(dyspnoea, thoracic pain, and well being) (h).
Respilift
Respivol
Figure 2: Representative patient using the combined devices Resp-
ivol and Respilift.
a difference between groups after intervention of 10 cmH
2
O
in the primary outcome.
All data was evaluated in terms of the intention-to-treat
approach (ITT); last observation carried forward (LOCF)was
used as a method of ITT and data are presented accordingly
[20].
Results were expressed as mean ± standard deviation
(SD) or 95% confidence interval (CI) for continuous variables
and frequency (percentage) for categorical variables. Test for
normality of data distribution was performed (Kolmogorov-
Smirnov test) a priori.Differences in the continuous variables
were then analyzed using an independent two-tailed 𝑡-test
for unpaired variables; otherwise, the nonparametric Mann-
Whitney 𝑈 test was used when appropriate. Categorical
variables were studied using the 𝜒2 test or Fisher’s exact test
when necessary.
For all analyses, an 𝛼-error <5% was considered to be
statistically significant.
3. Results
Sixty patients in active (𝑛 = 30) and control (𝑛 = 30) groups
represented the study cohort. All of them were recently
admitted to our centre after open cardiac (50 patients, 83%)
or thoracic (10 patients, 17%) surgery. No differences in
main anthropometric, clinical, and functional characteristics
were reported between groups (Tables 1 and 2). A coexisting
diagnosis of COPD was present in 10%, and in 5 of these
patients (8%) long-term oxygen therapy (LTOT) treatment
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Figure 3: Treatment difference (active versus control group) in the
primary study outcome evaluated at day 8 and day 14.MEP:maximal
expiratory pressure. ∗𝑃 < 0.05; ∗∗𝑃 < 0.001.
Table 1: General characteristics of patients enrolled.
Variables Active group(𝑛 = 30)
Control group
(𝑛 = 30) 𝑃
Age, years 66.8 ± 7.3 67.0 ± 9.8 0.941
Sex, M/F 24/6 20/10 0.243
BMI, kg⋅m2 25.4 ± 3.3 25.7 ± 4.1 0.727
COPD 2 (6) 4 (13) 0.389
LTOT 2 (6) 3 (10) 0.640
FiO2
†, % 28.0 ± 5.6 32.0 ± 4.0 0.413
Drop-out 2 (6) 2 (6) 1
Cardiothoracic surgical
intervention 0.622
CABG 10 (33) 7 (23)
Aortic valve replacement 8 (26) 11 (36)
Mitral valve repair 4 (13) 5 (16)
Mitral valve replacement 2 (6) 3 (10)
Pulmonary lobectomy 4 (13) 3 (10)
Pulmonary resection 2 (6) 0 (0)
Pneumonectomy 0 (0) 1 (3)
Variables described as mean ± SD or as frequency (%).
†Defined in LTOT patients only.
BMI: body mass index; COPD: chronic obstructive pulmonary disease;
LTOT: long-term oxygen therapy; FiO2: inspiratory fraction of oxygen;
CABG: coronary artery bypass graft.
was required. Overall, the drop-out rate was 6%, without any
group differences.
Table 2 shows pulmonary, exercise capacity, and quality
of life during the training period. After 14 days improvements
in dynamic lung volumes (FEV
1
, FVC, and VC), respiratory
muscle strength (MIP and MEP), gas exchange (PaO
2
/FiO
2
),
walking capacity at 6 MWT, and chronic dyspnoea scale
(MRC)were recorded in both groups;moreover, the improve-
ment of maximal expiratory performance (MEP), measured
as group difference both in absolute and % change between
enrolment and day 8 and day 14, was significantly higher in
active group (see Table 2 and Figure 3).
The daily trend of VAS dyspnoea, well-being and thoracic
pain, showed a similar and progressive improvement over
time in both groups: however, VAS dyspnoea improved faster
and more significantly at day 12 and day 14 of treatment in
the active when compared with control group (see Figure 4).
Moreover, the EMT did not worsen the thoracic pain, nor did
it alter its recovery course.
4. Discussion
Respilift, a respiratory device specifically aimed at EMT and
added to chest physiotherapy, has proved to be effective
over a 14-day period in patients recovering from CTS when
compared with patients performing a EMTwith a sham load.
The faster reduction of perceived dyspnoea together with
the absence of any negative interference on the recovery of
thoracic pain also proved feasibility and safety of the device.
Patients undergoing CTS may develop significant pul-
monary derangements and complications related to the
reduction of lung expansion and compliance; clinically, in
these patients dyspnoea and pain are the dominant symp-
toms, especially during minimal efforts. Moreover, these
pulmonary pathophysiological alterations are associated with
the risk of prolonging the hospital stay following surgery
[1, 2, 21]. Even if there are no consolidated scientific evidences
in this population, it is not clear whether surgical patients are
suitable candidates for a postoperative rehabilitation course
including chest physiotherapy [22–25]. Some clinical trials
showed this treatment as effective in improving pulmonary
expansion and respiratory muscle performance, furthermore
achieving a subsequent increase of physical capacities, gas
exchange, and quality of life perceived in the individual
patient [5–8].
To our knowledge there is only one experience [11, 12]
demonstrating that a 1-year home-based program including
combined lung expansion and expiratory muscle training
was associated with progressive improvements of MIP and
MEP and dyspnoea perception, in moderate COPD patients.
Our prospective study is the first showing that combination
of a lung expansion device (Respivol) and EMT (Respilift)
over 14 days is functionally and clinically associated with
more benefits than a sham training of Respilift; for both
groups chest physiotherapy with lung expansion was the only
technique used in the clinical practice in the population of
individuals recovering from cardiac or thoracic open surgery.
Thoracic expansion per se is clearly associated with
improvement of both pulmonary volumes and oxygenation
[22], general physical functions, and symptoms [23], thus
confirming the clinical usefulness of this chest physiotherapy
technique following thoracic or cardiac surgery, as prelim-
inary suggested by retrospective data in our centre [5]. In
addition, the selective use of a medium-term resistive EMT
course by the Respilift was associated with additional and
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Table 2: Study outcomes evaluated as change from the baseline.
Baseline Change from baseline at day 8 Change from baseline at day 14
Variables Active group(𝑛 = 30)
Control group
(𝑛 = 30)
Active group
(𝑛 = 30)
Control group
(𝑛 = 30)
Active group
(𝑛 = 30)
Control group
(𝑛 = 30)
FEV1, litres 1.9 ± 0.5 1.6 ± 0.6 0.0 ± 0.3 (0) 0.0 ± 0.2 (0) 0.1 ± 0.3 (5)
∗ 0.1 ± 0.2 (6)∗
% predicted 69.8 ± 18.4 64.7 ± 15.0 3.6 ± 10.2 (5) 2.6 ± 8.5 (4) 6.5 ± 10.1 (9)∗ 6.0 ± 10.6 (9)∗
FVC, litres 2.4 ± 0.7 2.1 ± 0.9 0.1 ± 0.5 (4) 0.0 ± 0.3 (0) 0.2 ± 0.6 (8)∗ 0.2 ± 0.4 (10)∗
% predicted 69.7 ± 15.0 66.3 ± 15.3 4.9 ± 11.2 (7)∗ 4.5 ± 11.8 (7) 8.8 ± 13.0 (13)∗∗ 8.3 ± 12.6 (13)∗
VC, litres 2.5 ± 0.5 2.3 ± 0.7 0.1 ± 0.3 (4)∗ 0.0 ± 0.4 (0) 0.2 ± 0.2 (8)∗∗ 0.3 ± 0.4 (13)∗
% predicted 68.3 ± 11.7 62.6 ± 13.6 3.7 ± 7.1 (5)∗ 3.6 ± 11.4 (6) 4.3 ± 5.1 (6)∗∗ 6.6 ± 12.3 (11)∗
IC, litres 2.8 ± 3.8 1.8 ± 0.7 −0.6 ± 3.8 (−21) 0.1 ± 0.6 (6) −0.5 ± 3.8 (−18) 0.2 ± 0.7 (11)
% predicted 74.4 ± 16.0 70.1 ± 14.7 3.4 ± 12.3 (5) 3.1 ± 13.2 (4) 5.1 ± 11.7 (7)∗ 6.5 ± 17.0 (9)
TLC, litres 5.4 ± 1.0 4.9 ± 1.2 0.2 ± 0.6 (4) 0.2 ± 0.9 (4) 0.1 ± 0.8 (2) 0.4 ± 1.0 (8)
% predicted 86.6 ± 13.1 84.6 ± 15.5 3.2 ± 10.3 (4) 3.5 ± 10.7 (4) 6.9 ± 13.5 (8)∗ 4.1 ± 15.9 (5)
RV, litres 2.7 ± 0.9 2.2 ± 1.1 −0.1 ± 1.0 (−4) 0.1 ± 0.8 (5) −0.0 ± 0.9 (0) 0.3 ± 1.0 (14)
% predicted 113.4 ± 37.2 97.5 ± 44.0 −7.1 ± 39.5 (−6) 6.3 ± 37.0 (6) 1.1 ± 29.8 (1) 15.7 ± 35.5 (16)∗
MIP, mmHg 59.9 ± 28.9 53.4 ± 21.3 8.1 ± 13.9 (14)∗ 7.5 ± 15.3 (14)∗ 13.3 ± 23.1 (22)∗ 13.4 ± 18.6 (25)∗
% predicted 60.5 ± 28.4 56.0 ± 20.5 9.5 ± 17.6 (16)∗ 5.6 ± 16.3 (10) 13.5 ± 22.5 (22)∗ 13.0 ± 16.5 (23)∗
MEP, mmHg 83.5 ± 23.7 76.8 ± 30.8 15.1 ± 16.1 (18)∗∗ 8.7 ± 17.5 (11)∗ 34.2 ± 24.9 (41)∗∗ 10.8 ± 18.3 (14)∗
% predicted 46.0 ± 14.6 43.5 ± 16.5 7.6 ± 10.7 (17)∗∗ 3.3 ± 15.5 (8) 26.1 ± 32.4 (57)∗∗ 7.4 ± 19.9 (17)
PaO2/FiO2, % 343.3 ± 47.8 337.6 ± 51.5 — — 22.9 ± 34.6 (7)
∗ 32.4 ± 52.6 (10)∗
PaCO2, mmHg 34.2 ± 4.8 35.5 ± 5.2 — — 0.8 ± 3.8 (2) −0.7 ± 4.4 (−2)
Distance walked at
6MWT, meters 308.9 ± 86.7 295.3 ± 108.4 — — 125.6 ± 76.1 (41)
∗∗ 108.0 ± 74.7 (37)∗∗
MRC, score 2.1 ± 0.5 2.0 ± 0.5 — — −1.0 ± 0.8 (−48)∗∗ −0.8 ± 0.3 (−40)∗∗
SF36FI, score 32.7 ± 6.6 33.5 ± 8.1 — — 3.2 ± 6.4 (10)∗ 4.5 ± 8.9 (13)∗
SF36ME, score 41.0 ± 11.0 41.5 ± 10.7 — — 3.9 ± 5.8 (10)∗ 3.2 ± 10.5 (8)
Variables described as mean ± SD. In parenthesis percentage of change from baseline.
No significant differences between active and control groups are reported in all baseline variables considered.
FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; VC: vital capacity; IC: inspiratory capacity; TLC: total lung capacity; RV:
residual volume; MIP: maximal inspiratory pressure; MEP: maximal expiratory pressure; PaO2/FiO2: arterial oxygen pressure on inspiratory oxygen fraction,
ratio; PaCO2: arterial carbon dioxide pressure; 6MWT: 6min walking test; MRC: medical research council; SF36 PC and MC: short form 36 health survey
questionnaire, physical and mental component, respectively.
∗
𝑃 < 0.05; ∗∗𝑃 < 0.001.
specific improvement of performance only in those muscle
groups which were trained (see Table 2 and Figure 3).
A significant point in favour of the use of EMT could
be considered the drop of individual’s symptoms recorded
over the study period, which was faster (from day 12 on) for
dyspnoea when the combination of techniques was used in
comparison with the use of volume-targeted lung expansion
alone (see in Figure 4). This result seems of true clinical
usefulness to those patients, since dyspnoea and thoracic
pain are the most relevant complaints after surgery [5, 23].
Interestingly enough, the reduction of the VAS score in
thoracic pain during the active EMT period paralleled that
recorded during sham resistive training and chest physiother-
apy. Indeed, one could have potentially expected that training
the expiratory muscle against a substantial resistive load
(30 cmH
2
O)might have been associatedwith increasing pain
or higher dropout rate, which was not the case in our study.
This result stands for a safety use of this training device in this
population after surgery with the aim to accelerate the fact
that the individual’s functional recovery and the reduction
of symptoms which may limit lung function, cough reflex
and consequently favour the late pulmonary complication
in the predisposed individuals [22]. Notwithstanding, we
missed any specific evaluation of cough performance (e.g.,
peak cough expiratory flow)whichmight have reinforced this
concept.
Despite the interesting and positive results in our trial,
these should be viewed with caution by readers due to several
limitations that need to be addressed. First, we did not know
the level of respiratorymuscle performance before admission
to surgery; despite the post-training level of both MIP and
MEP fell in the range of quasi-normality, it is likely that the
starting level of respiratorymuscle performancemay be a fac-
tor conditioning the change after training. As a matter of fact
around 10% of the patients in study had associated COPD;
thus they might have more benefit following specific training
of their inspiratory muscles [26]. Moreover, the percentage
of MIP load were patients working at was not measured
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Figure 4: Trend of symptoms reported by VAS score. VAS: visual analogic scale. ∗,∗∗𝑃 < 0.05 and 𝑃 < 0.001 between groups at the same
time, respectively.
before, and we cannot exclude that changes after training
would have been influenced by different level of inspiratory
muscle load. Nonetheless, our study specifically aimed at
training expiratory muscles that is the reason why changes
in intervention and control group significantly differed at
the end of the trial for MEP only and not for MIP. Since
the population was composed by patients recovering cardiac
surgery with only a minimal part of them being COPD, it
would be very difficult to speculate over effectiveness onMIP,
even in comparison with previous studies.
Second, the present findings were obtained once the
patients were stabilized and transferred from surgical units
to rehabilitation in a period between one to three weeks;
therefore, we cannot extrapolate the results (both in terms
of efficacy and feasibility) in a clinical phase closer to
the surgical intervention. Nonetheless, we cannot exclude a
spontaneous (althoughpartial) recovery of patient’s functions
in the phase between surgery and actual physiotherapy.
Finally and additionally, since this study lacks a long follow-
up period, we cannot exclude that obtained results would
have beenmaintained overweeks ormonths after the effective
training. A specific study would be able to answer this
question.
5. Conclusions
In conclusion this preliminary and controlled study has
shown that an easy-to-use respiratory device to train expi-
ratory muscle has additional effects when compared with a
sham training in the population of patients recovering the
open thoracic or cardiac surgery.
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